{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:06:10Z","timestamp":1784531170254,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013129","name":"Korea Ministry of SMEs and Startups","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"KHIDI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119704","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:28:08Z","timestamp":1783582088000},"page":"119704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer"],"prefix":"10.1016","volume":"201","author":[{"given":"Jihye","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hyeong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Jae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yoon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-5878","authenticated-orcid":false,"given":"Jae Ryoung","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Joo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-4909","authenticated-orcid":false,"given":"Jeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"30","key":"10.1016\/j.biopha.2026.119704_bib1","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119704_bib2","article-title":"Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119704_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405361","article-title":"Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches","volume":"14","author":"Guffanti","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119704_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"13","key":"10.1016\/j.biopha.2026.119704_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133316","article-title":"Phenformin as an anticancer agent: challenges and prospects","volume":"20","author":"Garcia Rubino","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119704_bib6","first-page":"57","article-title":"Metformin in cancer prevention and therapy","volume":"2","author":"Kasznicki","year":"2014","journal-title":"Ann. Transl. Med."},{"issue":"13","key":"10.1016\/j.biopha.2026.119704_bib7","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.3390\/cancers14133220","article-title":"The mechanism of action of biguanides: new answers to a complex question","volume":"14","author":"Di Magno","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2026.119704_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2011.06.038","article-title":"Use of metformin and the risk of ovarian cancer: a case-control analysis","volume":"123","author":"Bodmer","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"7503","key":"10.1016\/j.biopha.2026.119704_bib9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.biopha.2026.119704_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.27706","article-title":"Metformin intake is associated with better survival in ovarian cancer: a case-control study","volume":"119","author":"Kumar","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119704_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.biopha.2026.119704_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/bjc.2012.56","article-title":"Phenformin as prophylaxis and therapy in breast cancer xenografts","volume":"106","author":"Appleyard","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"35","key":"10.1016\/j.biopha.2026.119704_bib13","doi-asserted-by":"crossref","first-page":"56456","DOI":"10.18632\/oncotarget.10919","article-title":"Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2026.119704_bib14","first-page":"421","article-title":"Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin","volume":"31","author":"Lea","year":"2011","journal-title":"Anticancer. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119704_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2012.12.008","article-title":"LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin","volume":"23","author":"Shackelford","year":"2013","journal-title":"Cancer Cell."},{"issue":"59","key":"10.1016\/j.biopha.2026.119704_bib16","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.18632\/oncotarget.22012","article-title":"Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer","volume":"8","author":"Jackson","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2026.119704_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12935-024-03235-2","article-title":"The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19\/FGFR4 expression","volume":"24","author":"Lee","year":"2024","journal-title":"Cancer Cell. Int."},{"issue":"36","key":"10.1016\/j.biopha.2026.119704_bib18","doi-asserted-by":"crossref","first-page":"60342","DOI":"10.18632\/oncotarget.19466","article-title":"Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.biopha.2026.119704_bib19","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1111\/cas.14124","article-title":"Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer","volume":"110","author":"Park","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119704_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-61779-860-3_5","article-title":"Detection of apoptosis by TUNEL assay","volume":"887","author":"Kyrylkova","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"40","key":"10.1016\/j.biopha.2026.119704_bib21","doi-asserted-by":"crossref","first-page":"25842","DOI":"10.18632\/oncotarget.25386","article-title":"Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics","volume":"9","author":"Noack","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2026.119704_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41419-017-0137-x","article-title":"The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.biopha.2026.119704_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2024.06.011","article-title":"Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer","volume":"188","author":"Koh","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119704_bib24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.trecan.2021.03.001","article-title":"Therapeutic repurposing of biguanides in cancer","volume":"7","author":"Zhao","year":"2021","journal-title":"Trends Cancer"},{"issue":"24","key":"10.1016\/j.biopha.2026.119704_bib25","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.21037\/atm-20-1060","article-title":"Metformin and ovarian cancer: the evidence","volume":"8","author":"Urpilainen","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"21","key":"10.1016\/j.biopha.2026.119704_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112893","article-title":"Metformin improves ovarian cancer sensitivity to paclitaxel and platinum-based drugs: a review of in vitro findings","volume":"23","author":"Tossetta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119704_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/abbs\/gmx106","article-title":"Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells","volume":"50","author":"Saini","year":"2018","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"issue":"26","key":"10.1016\/j.biopha.2026.119704_bib28","doi-asserted-by":"crossref","first-page":"40767","DOI":"10.18632\/oncotarget.8194","article-title":"Repurposing metformin for cancer treatment: current clinical studies","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biopha.2026.119704_bib29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/106002809302701004","article-title":"Phenformin-induced lactic acidosis: a forgotten adverse drug reaction","volume":"27","author":"McGuinness","year":"1993","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2026.119704_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.29193","article-title":"The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells","volume":"136","author":"Orecchioni","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2026.119704_bib31","doi-asserted-by":"crossref","DOI":"10.3892\/or.2024.8810","article-title":"Progress in antitumor mechanisms and applications of phenformin (Review)","volume":"52","author":"Zhong","year":"2024","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2026.119704_bib32","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.18632\/oncotarget.14321","article-title":"Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma","volume":"8","author":"Petrachi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119704_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2014.08.012","article-title":"The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1\/hypoxia-inducible factor-1alpha signaling pathway in ELT-3 cells","volume":"399","author":"Tadakawa","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"32","key":"10.1016\/j.biopha.2026.119704_bib34","doi-asserted-by":"crossref","first-page":"51435","DOI":"10.18632\/oncotarget.9843","article-title":"Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport","volume":"7","author":"Velez","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2026.119704_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-016-0325-7","article-title":"NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo","volume":"9","author":"Zhang","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119704_bib36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ygyno.2014.10.011","article-title":"Old drug, new trick: repurposing metformin for gynecologic cancers?","volume":"135","author":"Febbraro","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119704_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131207","article-title":"Phenformin induces cell cycle change, apoptosis, and mesenchymal-epithelial transition and regulates the AMPK\/mTOR\/p70s6k and MAPK\/ERK pathways in breast cancer cells","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.biopha.2026.119704_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2026.119704_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.canlet.2011.03.026","article-title":"Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells","volume":"307","author":"Xi","year":"2011","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119704_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010255","article-title":"Expression and functional contribution of different organic cation transporters to the cellular uptake of doxorubicin into human breast cancer and cardiac tissue","volume":"23","author":"Otter","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:42:02Z","timestamp":1784529722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["S0753332226007407"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119704","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119704"}}